Rani Therapeutics To Present Data On Oral Delivery Of An Ustekinumab Biosimilar Via The RaniPill Capsule At Digestive Disease Week 2024
Portfolio Pulse from Benzinga Newsdesk
Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company, announced its participation in Digestive Disease Week 2024, where it will present data on the oral delivery of an ustekinumab biosimilar via its RaniPill capsule. The presentations will cover both clinical and preclinical data demonstrating the high bioavailability of the orally administered ustekinumab biosimilar compared to subcutaneous injections in humans and canines.
May 09, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rani Therapeutics is poised to present significant data on its RaniPill capsule at DDW 2024, showcasing the oral delivery of an ustekinumab biosimilar with promising bioavailability results.
The announcement of Rani Therapeutics' participation in DDW 2024 to present data on the RaniPill capsule is likely to generate positive investor sentiment. The focus on the oral delivery of biologics, a significant area of interest in the pharmaceutical industry, coupled with the promising bioavailability results compared to subcutaneous injections, positions RANI for potential short-term gains. The relevance of this news to RANI is direct, given the company's focus on the RaniPill capsule as a key product. The importance is high due to the potential market impact of successful oral delivery systems for biologics. Confidence in this analysis is based on the clear connection between the company's core business and the news.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100